Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients

According to current guidelines, in chronic lymphocytic leukemia (CLL), only the TP53 molecular status must be evaluated prior to every treatment’s initiation. However, additional heterogeneous genetic events are known to confer a proliferative advantage to the tumor clone and are associated with progression and treatment failure in CLL patients. Here, we describe the implementation of a comprehensive targeted sequencing solution that is suitable for routine clinical practice and allows for the detection of the most common somatic single-nucleotide and copy number variants in genes relevant to CLL. We demonstrate that this cost-effective strategy achieves variant detection with high accuracy, specificity, and sensitivity. Furthermore, we identify somatic variants and copy number variations in genes with prognostic and/or predictive value, according to the most recent literature, and the tool provides evidence about subclonal events. This next-generation sequencing (NGS) capture-based target assay is an improvement on current approaches in defining molecular prognostic and/or predictive variables in CLL patients.

[1]  F. Solé,et al.  A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms , 2021, Cancers.

[2]  M. Hernández-Sánchez,et al.  From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct , 2021, Cancers.

[3]  A. Wiestner Validating genomic tools for precision medicine in CLL: ERIC leads the way , 2021, Haematologica.

[4]  M. Tormo,et al.  Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project , 2020, Haematologica.

[5]  Rajesh R Singh,et al.  Next-Generation Sequencing in High-Sensitive Detection of Mutations in Tumors: Challenges, Advances and Applications. , 2020, The Journal of molecular diagnostics : JMD.

[6]  E. Campo,et al.  Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study , 2020, Haematologica.

[7]  G. Gaidano,et al.  Precision Medicine Management of Chronic Lymphocytic Leukemia , 2020, Cancers.

[8]  Benjamin L. Ebert,et al.  Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes , 2019, Nature Medicine.

[9]  J. Cigudosa,et al.  Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2019, British journal of haematology.

[10]  I. Zalcberg,et al.  Multidisciplinary diagnostics of chronic lymphocytic leukemia: European Research Initiative on CLL - ERIC recommendations , 2019, Hematology, transfusion and cell therapy.

[11]  F. Bosch,et al.  Chronic lymphocytic leukaemia: from genetics to treatment , 2019, Nature Reviews Clinical Oncology.

[12]  R. Foà,et al.  Another step forward in the 20-year history of IGHV mutations in chronic lymphocytic leukemia , 2019, Haematologica.

[13]  J. Byrd,et al.  iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. , 2018, Blood.

[14]  L. Lopez,et al.  Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia , 2017, Leukemia.

[15]  A. López-Guillermo,et al.  Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. , 2015, Blood.

[16]  Martin A. Nowak,et al.  Mutations driving CLL and their evolution in progression and relapse , 2015, Nature.

[17]  A. Valencia,et al.  Non-coding recurrent mutations in chronic lymphocytic leukaemia , 2015, Nature.

[18]  E. Campo,et al.  Recurrent mutations refine prognosis in chronic lymphocytic leukemia , 2014, Leukemia.

[19]  M. Hallek,et al.  Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.